This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1988;259(22):3225.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

MORE INTENSIVE EFFORTS to avoid pregnancies in patients being treated with isotretinoin (Accutane) are coming.

A dermatologic drugs advisory committee to the Food and Drug Administration (FDA) has, among other things, recommended unanimously that the drug be allowed to remain on the market with revised labeling.

Frank E. Young, MD, FDA commissioner, said the agency would move quickly to evaluate the committee's recommendations and to carry out those that would have the greatest impact on curbing the serious side effects associated with the drug.

Ever since it was approved for cystic acne (JAMA 1982;247:1800-1801), the drug has been contraindicated in women who are pregnant or unwilling to prevent pregnancy while under treatment. Despite the warnings, fetal malformations have occurred. To date, 62 birth defects attributed to the drug have been reported.

Extrapolating nationwide from data obtained among Medicaid patients in Michigan and the Group Health Cooperative in Seattle, FDA scientists . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?